Recombinant human erythropoietin in a triplet pregnancy: a case report

J Reprod Med. 2005 Nov;50(11):863-6.

Abstract

Background: Women carrying triplets are at greater risk for both anemia, due to the increased demands of the developingfetuses, and peripartum hemorrhage. Jehovah's witnesses are a unique obstetric population since women of this faith refuse blood transfusion.

Case: A Jehovah's Witness with a triplet pregnancy was successfully administered recombinant human erythropoietin (rHuEpo), 200 IU/kg 3 times per week subcutaneously, in order to correct her peripartum anemia. No side effects were observed during rHuEpo therapy, and the patient delivered healthy triplets.

Conclusion: rHuEpo can be safely administered, with a beneficial effect in pregnancy, and seems to be an effective option in preventing transfusions as demonstrated in this case in a Jehovah's Witness.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anemia, Iron-Deficiency / drug therapy*
  • Blood Transfusion
  • Erythropoietin / therapeutic use*
  • Female
  • Humans
  • Jehovah's Witnesses*
  • Pregnancy
  • Pregnancy Outcome
  • Recombinant Proteins
  • Triplets*

Substances

  • Recombinant Proteins
  • Erythropoietin